Literature DB >> 19119097

Sampling of melanocytic nevi for research purposes: a prospective, pilot study to determine effect on diagnosis.

Scott R Florell1, Bruce R Smoller, Kenneth M Boucher, Douglas Grossman, Ronald M Harris, Glen M Bowen, Sancy A Leachman.   

Abstract

BACKGROUND: Research on melanocytic nevi predominantly utilizes formalin-fixed, paraffin-embedded tissue, largely limiting research to morphologic and immunohistochemical observations. Withholding portions of fresh nevus tissue for molecular studies could result in the loss of important diagnostic material.
OBJECTIVE: This study prospectively evaluated melanocytic nevi for histologic homogeneity to determine if using a portion for research would have affected diagnosis.
METHODS: Thirty-three subjects were enrolled in a prospective study in which pigmented lesions were chosen for biopsy on a clinical basis. Lesions were sectioned and each piece submitted in a separate block (mean, 2.7; range 2-5 blocks per lesion). Slides from nevi were examined in two phases. In phase I, sections of nevi were randomized and a diagnosis was rendered for each section of nevus. In phase II, the dermatopathologist reviewed all slides for each nevus as a case, similar to the original interpretation of the lesion provided to the clinician. Diagnoses from phases I and II were compared with the original diagnosis.
RESULTS: Case material included 51 melanocytic lesions from 31 subjects. The phase I diagnosis matched the original diagnosis for 99 of 121 slides that showed a melanocytic lesion (82%). The phase II diagnosis matched the original diagnosis for 45 of 51 specimens (88%). LIMITATIONS: The study was limited by: a small number of specimens; the clinician could have chosen clinically homogeneous nevi for biopsy; effect of interobserver and intraobserver variability on diagnosis.
CONCLUSIONS: For the majority of melanocytic nevi in this study, the diagnostic information present in one section of a melanocytic nevus could be extrapolated to the remainder of the specimen without adverse consequences from a diagnostic or therapeutic perspective.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19119097     DOI: 10.1016/j.jaad.2008.07.020

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  6 in total

1.  Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi.

Authors:  Agnessa Gadeliya Goodson; Scott R Florell; Kenneth M Boucher; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2009-12-16       Impact factor: 11.527

2.  Increased shedding of HU177 correlates with worse prognosis in primary melanoma.

Authors:  Heather K Hamilton; Amy E Rose; Paul J Christos; Richard L Shapiro; Russell S Berman; Madhu Mazumdar; Michelle W Ma; Daniel Krich; Leonard Liebes; Peter C Brooks; Iman Osman
Journal:  J Transl Med       Date:  2010-02-23       Impact factor: 5.531

3.  Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention.

Authors:  Agnessa Gadeliya Goodson; Murray A Cotter; Pamela Cassidy; Mark Wade; Scott R Florell; Tong Liu; Kenneth M Boucher; Douglas Grossman
Journal:  Clin Cancer Res       Date:  2009-11-17       Impact factor: 12.531

4.  Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma.

Authors:  Bao-Jin Wu; Wen-Peng Li; Cheng Qian; Wei Ding; Zhong-Wen Zhou; Hua Jiang
Journal:  Tumour Biol       Date:  2012-11-21

5.  Theory of sampling and its application in tissue based diagnosis.

Authors:  Klaus Kayser; Holger Schultz; Torsten Goldmann; Jürgen Görtler; Gian Kayser; Ekkehard Vollmer
Journal:  Diagn Pathol       Date:  2009-02-16       Impact factor: 2.644

6.  Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens.

Authors:  Daniela Furrer; Simon Jacob; Chantal Caron; François Sanschagrin; Louise Provencher; Caroline Diorio
Journal:  Diagn Pathol       Date:  2013-02-04       Impact factor: 2.644

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.